Overview

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
Participant gender:
Summary
This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia. Primary efficacy variable is Wake time After Sleep Onset (WASO), averaged over all in-treatment time points and measured by polysomnography (PSG).
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Mirtazapine